{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:14:06Z","timestamp":1793366046685,"version":"4.5.0"},"reference-count":61,"publisher":"American Society for Clinical Investigation","issue":"10","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIAID\/NIH","award":["U19AI142785"],"award-info":[{"award-number":["U19AI142785"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,23]]},"abstract":"<jats:p>\n                    A major challenge in managing acute viral infections is ameliorating disease when treatment is delayed. Previously, we reported the success of a 2-pronged mAb and antiviral remdesivir therapeutic approach to treat advanced illness in rhesus monkeys infected with Marburg virus (MARV). Here, we explored the benefit of a similar combination therapy for\n                    <jats:italic>Sudan ebolavirus<\/jats:italic>\n                    (Sudan virus; SUDV) infection. Importantly, no licensed anti-SUDV therapeutics currently exist, and infection of rhesus macaques with SUDV results in a rapid disease course similar to MARV with a mean time to death of 8.3 days. When initiation of therapy with either remdesivir or a pan-ebolavirus mAb cocktail (MBP431) was delayed until 6 days after inoculation, only 20% of macaques survived. In contrast, when remdesivir and MBP431 treatment were combined beginning 6 days after inoculation, significant protection (80%) was achieved. Our results suggest that combination therapy may be a viable treatment for patients with advanced filovirus disease that warrants further clinical testing in future outbreaks.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.159090","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T12:52:17Z","timestamp":1649767937000},"source":"Crossref","is-referenced-by-count":50,"title":["Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease"],"prefix":"10.1172","volume":"7","author":[{"given":"Robert W.","family":"Cross","sequence":"first","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Bornholdt","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-2077","authenticated-orcid":true,"given":"Abhishek N.","family":"Prasad","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Woolsey","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-6935","authenticated-orcid":true,"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna M.","family":"Abelson","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Shestowsky","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioudmila A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Bunyan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Geisbert","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Dobias","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Fenton","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle P.","family":"Porter","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-1024","authenticated-orcid":true,"given":"Larry","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc., San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":true,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory and"},{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"B1","article-title":"Filovirus disease outbreaks: a chronological overview","volume":"10","author":"Languon","year":"2019","journal-title":"Virology (Auckl)"},{"issue":"suppl 1","key":"B2","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1086\/514285","article-title":"Human infection due to Ebola virus, subtype C\u00f4te d\u2019Ivoire: clinical and biologic presentation","volume":"179","author":"Formenty","year":"1999","journal-title":"J Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90925-7"},{"issue":"8011","key":"B4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(77)92001-3","article-title":"Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent","volume":"1","author":"Bowen","year":"1977","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000536"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2004.03.003"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.142"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/v13071388"},{"issue":"suppl 5","key":"B9","doi-asserted-by":"crossref","first-page":"S649","DOI":"10.1093\/infdis\/jiy303","article-title":"Postexposure protective efficacy of T-705 (Favipiravir) against Sudan virus infection in guinea pigs","volume":"218","author":"Rahim","year":"2018","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1914985117"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.12.004"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.12.005"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08040-w"},{"key":"B14","doi-asserted-by":"crossref","unstructured":"Kuang E, et al. Reversion of ebolavirus disease from a single intramuscular injection of a pan-ebolavirus immunotherapeutic. [preprint]. https:\/\/doi.org\/10.1101\/2022.01.06.475142 Posted on bioRxiv January 6, 2022","DOI":"10.3390\/pathogens11060655"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"issue":"11","key":"B16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiaa290","article-title":"Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus","volume":"222","author":"Porter","year":"2020","journal-title":"J Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9242"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922083117"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2423-5"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.015720"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102685"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934"},{"key":"B26","unstructured":"National Institutes of Health. Anti-SARS-CoV-2 Monoclonal Antibodies. https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/anti-sars-cov-2-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/ Updated December 16, 2021. Accessed December 18, 2021"},{"key":"B27","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure Updated December 8, 2021. Accessed December 18, 2021"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.05.020"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022926"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22240"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27259"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab358"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"B34","doi-asserted-by":"crossref","unstructured":"U.S. Food and Drug Administration. FDA Approves First Treatment for COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19 Updated October 22, 2020. Accessed December 18, 2020","DOI":"10.1002\/cpu.30542"},{"issue":"6","key":"B35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B36","unstructured":"Pfizer, Inc. Pfizer Announces Additional Phase 2\/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-additional-phase-23-study-results Updated December 14, 2021. Accessed January 5, 2022"},{"key":"B37","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 Updated December 22, 2021. Accessed January 6, 2022"},{"key":"B38","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain Updated December 23, 2021. Accessed January 6, 2022"},{"issue":"suppl 1","key":"B39","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1086\/514280","article-title":"Recombinant human monoclonal antibodies to Ebola virus","volume":"179","author":"Maruyama","year":"1999","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.7.6024-6030.1999"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.12.6408-6412.2002"},{"key":"B42","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch Virol Suppl"},{"issue":"suppl 1","key":"B43","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/514310","article-title":"Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections","volume":"179","author":"Jahrling","year":"1999","journal-title":"J Infect Dis"},{"issue":"suppl 2","key":"B44","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1086\/520587","article-title":"Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates","volume":"196","author":"Jahrling","year":"2007","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030009"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200409109"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.251"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604330"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.113"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.08.003"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01438-20"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.05.013"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30516-3"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500306"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250780"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.10.031"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00561-09"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1177\/0300985813485099"},{"key":"B61","unstructured":"R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/ Updated 2022. Accessed May 3, 2022"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/159090\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:34:24Z","timestamp":1779147264000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/159090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,5,23]]}},"alternative-id":["10.1172\/jci.insight.159090"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.159090","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"article-number":"e159090"}}